# A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

> **NCT06503614** · PHASE2 · RECRUITING · sponsor: **John Sfakianos** · enrollment: 60 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer
- Non-Muscle Invasive Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Monalizumab

## Key facts

- **NCT ID:** NCT06503614
- **Lead sponsor:** John Sfakianos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-12-22
- **Final completion:** 2032-12-22
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503614, "A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06503614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*